Compliance Trends of GMP-Grade Reagents in Cell and Gene Therapy and In Vitro Diagnostics

Regulatory-driven increase in material quality requirements

Due to individualized starting materials, small production batches, and short shelf lives, cell and gene therapy products have particularly stringent quality requirements for production reagents and consumables. Domestic and international drug regulatory agencies have continuously emphasized material traceability, adventitious agent control, and supplier qualification management in relevant guidelines. GMP-grade reagents have gradually become a common choice in the production of stem cells, immune cells, and viral vectors due to their relatively comprehensive batch records and quality systems. Although regulations do not necessarily mandate that all reagents be labeled "GMP-grade," companies typically need to demonstrate the quality controllability of critical materials during registration and filing, which has driven the application of GMP-grade reagents in the advanced therapy field.

The in vitro diagnostic industry shows a similar trend. If the quality of key raw materials for companion diagnostic reagents, nucleic acid detection reagents, and chemiluminescence reagents—such as primer probes, antigens and antibodies, enzymes, and standards—is unstable, it may affect the accuracy and comparability of clinical test results. In some inspection points of the Good Manufacturing Practice for In Vitro Diagnostic Reagent Production, explicit requirements are set for tiered management of critical materials, supplier audits, and incoming inspection, providing an institutional basis for the introduction of GMP-grade reagents.

Residual control and supply chain transparency

In cell and gene therapy products, residual substances such as exogenous DNA, host cell proteins, antibiotics, cytokines, and magnetic bead residues must be strictly controlled. GMP-grade reagents generally provide more detailed residual detection methods and validation data, helping companies assess the residual risk of reagent components in the final product. For example, antibodies or cytokines used for T cell activation, if they contain animal-derived components or undeclared stabilizers, may become safety concerns. Regarding supply chain transparency, regulatory agencies are increasingly focused on the original sources and processing pathways of critical materials. If GMP-grade reagent suppliers can provide a complete bill of materials and risk analysis from raw materials to finished products, it will help sponsors establish a material traceability system.

Pay attention to whether suppliers provide animal-origin-free or recombinant expression statements to reduce TSE/BSE risks.

Verify whether residual solvent, heavy metal, and endotoxin testing data meet the acceptable standards for the final product.

Require suppliers to provide advance notice of process changes so that the impact on products under development can be assessed.

Localized supply and future trends

Affected by global supply chain uncertainty and cold chain transportation costs, the demand for localized supply of GMP-grade reagents is increasing. Domestic companies have begun to establish production lines for molecular biology reagents, cell culture media, and purification resins that conform to GMP concepts, striving to strike a balance between cost and compliance. In the future, GMP-grade reagents may be further segmented by application scenario, such as serum-free, xeno-free reagents dedicated to cell therapy, or high-uniformity standards dedicated to in vitro diagnostics. In addition, the popularization of digital quality systems and electronic batch records will also help facilitate data exchange and remote audits between GMP-grade reagent suppliers and pharmaceutical companies. It should be noted that when selecting products, companies should combine process validation data and cannot replace actual risk assessment solely with a "GMP-grade" label. Only by matching material grade, usage stage, and quality system can the value of GMP-grade reagents in compliance and process robustness be truly realized.